The Newer-Generation DES, Really Nothing to Special?
- PMID: 38863254
- PMCID: PMC11169914
- DOI: 10.4070/kcj.2024.0135
The Newer-Generation DES, Really Nothing to Special?
Conflict of interest statement
The author has no financial conflicts of interest.
Comment on
-
Efficacy and Safety of Sirolimus-Eluting Stent With Biodegradable Polymer Ultimaster™ in Unselected Korean Population: A Multicenter, Prospective, Observational Study From Korean Multicenter Ultimaster Registry.Korean Circ J. 2024 Jun;54(6):339-350. doi: 10.4070/kcj.2024.0023. Epub 2024 Apr 22. Korean Circ J. 2024. PMID: 38767441 Free PMC article.
References
-
- Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2:291–299. - PubMed
-
- Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol. 2013;61:536–544. - PubMed
-
- Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–1288. - PubMed
-
- Kobayashi T, Sotomi Y, Suzuki S, et al. Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials. Cardiovasc Interv Ther. 2020;35:250–258. - PubMed
-
- Taglieri N, Bruno AG, Ghetti G, et al. Target lesion failure with current drug-eluting stents: evidence from a comprehensive network meta-analysis. JACC Cardiovasc Interv. 2020;13:2868–2878. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
